Trial · NCT02058641
Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT02058641, Phase 1, Completed, GlaxoSmithKline
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM). Trials, record NCT02058641. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02058641
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)
- NCT number
- NCT02058641
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 9 participants, actual
- Lead sponsor
- GlaxoSmithKline
- Conditions
- Atherosclerosis
- Interventions
- Darapladib
- First posted
- 2014-02-10
- Last updated
- 2017-05-15
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Macrophage cell count and surface expression of markers of M1 and M2 polarization in blister fluid | Up to 6 weeks | To assess the effect of an 11 day course of once daily darapladib EC 160 mg on the number and phenotype (M1/M2 polarization) of macrophages isolated from blisters on subjects with type 2 diabetes mellitus (blisters induced by exposure to cantharidin for 48 hours). Biomarkers may include, but not be limited to: Cluster of differentiation (CD)11b, CD14, CD16, CD33, CD40, CD64, CD68, CD86, CD163, CD206, C-C chemokine receptor type 2 (CCR2), CX3 chemokine receptor 1 (CX3CR1) |
| Secondary | Number of monocytes and surface expression of markers of M1 or M2 polarization in peripheral blood | Up to 6 weeks | To assess the effect of an 11 day course of once daily darapladib EC 160 mg on the number and phenotype of monocytes (M1/M2 ratio) isolated from peripheral blood of subjects with type 2 diabetes mellitus. Biomarkers may include, but not be limited to: CD11b, CD14, CD16, CD40, CD64, CD68, CD163, CD206 |
| Secondary | Enzymatic activity of Lp-PLA2 in blister fluid | Up to 6 weeks | Blood samples will be taken for assessments of enzymatic activity of Lp-PLA2 (measured by hydrolysis of radio-labeled platelet-activating factor \[PAF\]) |
| Secondary | Total cell count, lymphocyte count, neutrophil count and macrophage count in blister fluid | Up to 6 weeks | Blister fluids will be collected to assess the differences in blister phenotype (volume, appearance, cellularity) between subjects |
| Secondary | Concentrations of soluble mediators of macrophage polarization | Up to 6 weeks | Soluble mediators will be measured in blister fluid assessed by a multiplex platform (Meso scale delivery or Luminex) and may include but not be restricted to matrix metalloproteinase 9 (MMP9), interleukin (IL)-12, IL-23, IL-10, interferon-gamma, tumor necrosis factor-alpha, IL-1 beta, IL-6, IL-8, IL-4, IL-13, transforming growth factor-beta, monocyte chemotactic protein-1 and C-reactive protein |
| Secondary | Time to healing of cantharidin-induced blisters | Up to 8 weeks | Blisters will be considered to be healed when the blister cover has fallen off and the blister area becomes dry |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02058641
GET https://conductscience.org/api/trials/v1/NCT02058641/registered